Conference Coverage
Conference Coverage
Islet, kidney transplants boost survival in type 1 diabetes
“Although islet transplantation has previously been shown to improve glycemic control, compared with conventional insulin therapy in recent...
Conference Coverage
Muvalaplin and olpasiran show early promise in lowering Lp(a)
“For the first time we have an oral agent” that lowers Lp(a) levels. However, “we will still need to determine if this leads to a reduction in...
Conference Coverage
Should clinic BP be routinely measured lying down?
The data revealed that 16% of those without seated hypertension had supine hypertension, while 74% of those with seated hypertension had supine...
Conference Coverage
SGLT2 inhibitors: No benefit or harm in hospitalized COVID-19
“I think the most important take-home message here is that the use of these medications appears to be safe even in really acutely ill hospitalized...
Conference Coverage
Heart attack deaths static in those with type 1 diabetes
“Clinicians have to be aware of the absence of the declined mortality trend in people with type 1 diabetes having a first-time myocardial...
Latest News
‘New dawn’ for aldosterone as drug target in hypertension?
The medication lowered systolic blood pressure significantly more than placebo, with the greatest effects seen in adults with obesity.
Conference Coverage
Low-dose aspirin cuts type 2 diabetes risk in over-65s
“At this time, our findings are exploratory but ignite the debate of the important role that anti-inflammatory approaches may play in preventing...
Conference Coverage
More weight loss linked with more benefit in STEP-HFpEF
“The outcomes we’ve already seen in STEP-HFpEF were largely symptomatic, which are extraordinarily important, but there may be a completely...
Conference Coverage
ESC backs SGLT2 inhibitor plus GLP-1 in diabetes with high CVD risk
Another major change in the new ESC guideline revision is introduction of a CVD risk calculator intended to estimate the risk among people with...
Conference Coverage
Wegovy scores HFpEF benefits in people with obesity
The results “indicate that treatment with semaglutide is a valuable therapeutic approach in the management of patients with HFpEF and obesity.”
Conference Coverage
Growth hormone links with worse T2D control in adolescents
Researchers hope to “leverage these data to find predictive markers” that could identify adolescents with type 2 diabetes “at risk for...